Zobrazeno 1 - 2
of 2
pro vyhledávání: '"HIV/TB co-treatment Rifampicin"'
Autor:
Daniel W. Gunda, Samuel E. Kalluvya, Christa Kasang, Benson R. Kidenya, Bonaventura C. Mpondo, Hartwig Klinker
Publikováno v:
Alexandria Journal of Medicine, Vol 53, Iss 3, Pp 271-279 (2017)
Background: Tuberculosis/Human Immunodeficiency Virus (TB/HIV) is a very common co-infection which carries a high mortality rate. Though World Health Organization recommends co-treatment of TB/HIV to improve its outcome, Rifampicin potentially induce
Externí odkaz:
https://doaj.org/article/edb17de39d0d4273ba5d9d3716f04880
Autor:
Benson R. Kidenya, Christa Kasang, Hartwig Klinker, Bonaventura C.T. Mpondo, Samuel E. Kalluvya, Daniel W. Gunda
Publikováno v:
Alexandria Journal of Medicine; Vol 53, No 3 (2017); 271-279
Alexandria Journal of Medicine, Vol 53, Iss 3, Pp 271-279 (2017)
Alexandria Journal of Medicine, Vol 53, Iss 3, Pp 271-279 (2017)
Background: Tuberculosis/Human Immunodeficiency Virus (TB/HIV) is a very common co-infection which carries a high mortality rate. Though World Health Organization recommends co-treatment of TB/HIV to improve its outcome, Rifampicin potentially induce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2fbd0561e401264f85d2d506ddea25a
https://doi.org/10.1016/j.ajme.2016.10.001
https://doi.org/10.1016/j.ajme.2016.10.001